Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.71 |
| ▸ | ANPEP | P15144 | 3/20 | 0.71 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.32 |
| ▸ | PEPD | P12955 | 2/20 | 0.32 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14951723 | 0.89 | MMP2 (0.64) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL30476594 | 0.83 | MMP2 (1.00) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL30370233 | 0.83 | MMP2 (0.79) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL16171927 | 0.83 | MMP2 (1.00) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL14941114 | 0.83 | MMP2 (0.79) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL13768839 | 0.83 | MMP2 (0.70) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL13494285 | 0.83 | MMP2 (0.70) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL13841888 | 0.83 | MMP2 (0.70) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL20215871 | 0.83 | MMP2 (0.70) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL15482322 | 0.83 | MMP2 (0.70) | MMP2ANPEPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | Antios Therapeutics, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | HAVCR2, NR1H4, HCCS | MMP2 1211/4885ANPEP 1014/4885DPP7 783/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | MMP2 1211/4885ANPEP 1014/4885DPP7 783/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | MMP2 710/4885ANPEP 853/4885DPP7 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.